Aveda receives second “Proggy”
This article was originally published in The Rose Sheet
Executive Summary
People for the Ethical Treatment of Animals (PETA) awards plant-derived personal-care brand the 2008 PETA Progress (Proggy) Award for "Best Cruelty-Free Spa Products." Aveda's 2008 spa and professional product launches included Green Science skin care, the firm notes. PETA's Proggy Awards recognize animal-friendly achievements in seven categories, including clothing and accessories, food, science and personal-care products; the awards are in their sixth year. In 2004, Aveda was honored for its "Best Cruelty-Free Personal-Care Products." For 30 years, Aveda has focused on offering consumers "the highest quality products and services that have the least environmental impact," says Chuck Bennett, vice president of earth & community care. "This singular mission guides all business decisions at Aveda and inspires us to become better stewards of the Earth," he adds. Estee Lauder, which owns the Aveda and Origins brands, was cited in 2007 at the Personal Care Product Council's annual meeting as having one of the leading corporate responsibility programs in the personal-care industry (1"The Rose Sheet" March 26, 2007, p. 6)
You may also be interested in...
Everybody Wins: Corporate Responsibility Programs That Also “Sell Soap”
Personal care companies increasingly are developing programs that not only reduce their impact on the environment and give back to the local and global community, but award benefits to the business as well, according to Jennifer Nash, executive director of the corporate responsibility initiative at Harvard University's John F. Kennedy School of Government
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.